<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39354697</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1474-9726</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Oct</Month><Day>01</Day></PubDate></JournalIssue><Title>Aging cell</Title><ISOAbbreviation>Aging Cell</ISOAbbreviation></Journal><ArticleTitle>Dysregulated nicotinamide adenine dinucleotide metabolome in patients hospitalized with COVID-19.</ArticleTitle><Pagination><StartPage>e14326</StartPage><MedlinePgn>e14326</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/acel.14326</ELocationID><Abstract><AbstractText>Nicotinamide adenine dinucleotide (NAD<sup>+</sup>) depletion has been postulated as a contributor to the severity of COVID-19; however, no study has prospectively characterized NAD<sup>+</sup> and its metabolites in relation to disease severity in patients with COVID-19. We measured NAD<sup>+</sup> and its metabolites in 56 hospitalized patients with COVID-19 and in two control groups without COVID-19: (1) 31 age- and sex-matched adults with comorbidities, and (2) 30 adults without comorbidities. Blood NAD<sup>+</sup> concentrations in COVID-19 group were only slightly lower than in the control groups (p &lt; 0.05); however, plasma 1-methylnicotinamide concentrations were significantly higher in patients with COVID-19 (439.7 ng/mL, 95% CI: 234.0, 645.4 ng/mL) than in age- and sex-matched controls (44.5 ng/mL, 95% CI: 15.6, 73.4) and in healthy controls (18.1 ng/mL, 95% CI 15.4, 20.8; p &lt; 0.001 for each comparison). Plasma nicotinamide concentrations were also higher in COVID-19 group and in controls with comorbidities than in healthy control group. Plasma concentrations of 2-methyl-2-pyridone-5-carboxamide (2-PY), but not NAD<sup>+</sup>, were significantly associated with increased risk of death (HR = 3.65; 95% CI 1.09, 12.2; p = 0.036) and escalation in level of care (HR = 2.90, 95% CI 1.01, 8.38, p = 0.049). RNAseq and RTqPCR analyses of PBMC mRNA found upregulation of multiple genes involved in NAD<sup>+</sup> synthesis as well as degradation, and dysregulation of NAD<sup>+</sup>-dependent processes including immune response, DNA repair, metabolism, apoptosis/autophagy, redox reactions, and mitochondrial function. Blood NAD<sup>+</sup> concentrations are modestly reduced in COVID-19; however, NAD<sup>+</sup> turnover is substantially increased with upregulation of genes involved in both NAD<sup>+</sup> biosynthesis and degradation, supporting the rationale for NAD+ augmentation to attenuate disease severity.</AbstractText><CopyrightInformation>© 2024 The Author(s). Aging Cell published by Anatomical Society and John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Valderrábano</LastName><ForeName>Rodrigo J</ForeName><Initials>RJ</Initials><Identifier Source="ORCID">0000-0002-4910-3997</Identifier><AffiliationInfo><Affiliation>Research Program in Men's Health: Aging and Metabolism, Boston Claude D. Pepper Older Americans Independence Center, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wipper</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Research Program in Men's Health: Aging and Metabolism, Boston Claude D. Pepper Older Americans Independence Center, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pencina</LastName><ForeName>Karol Mateusz</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>Research Program in Men's Health: Aging and Metabolism, Boston Claude D. Pepper Older Americans Independence Center, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Migaud</LastName><ForeName>Marie</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, Mitchell Cancer Institute, University of South Alabama, Mobile, Alabama, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shang</LastName><ForeName>Yili Valentine</ForeName><Initials>YV</Initials><AffiliationInfo><Affiliation>Research Program in Men's Health: Aging and Metabolism, Boston Claude D. Pepper Older Americans Independence Center, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Latham</LastName><ForeName>Nancy K</ForeName><Initials>NK</Initials><AffiliationInfo><Affiliation>Research Program in Men's Health: Aging and Metabolism, Boston Claude D. Pepper Older Americans Independence Center, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Montano</LastName><ForeName>Monty</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-8738-2838</Identifier><AffiliationInfo><Affiliation>Research Program in Men's Health: Aging and Metabolism, Boston Claude D. Pepper Older Americans Independence Center, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cunningham</LastName><ForeName>James M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Division of Hematology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wilson</LastName><ForeName>Lauren</ForeName><Initials>L</Initials><Identifier Source="ORCID">0009-0004-0692-4201</Identifier><AffiliationInfo><Affiliation>Research Program in Men's Health: Aging and Metabolism, Boston Claude D. Pepper Older Americans Independence Center, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peng</LastName><ForeName>Liming</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Research Program in Men's Health: Aging and Metabolism, Boston Claude D. Pepper Older Americans Independence Center, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Memish-Beleva</LastName><ForeName>Yusnie</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Research Program in Men's Health: Aging and Metabolism, Boston Claude D. Pepper Older Americans Independence Center, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bhargava</LastName><ForeName>Avantika</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Research Program in Men's Health: Aging and Metabolism, Boston Claude D. Pepper Older Americans Independence Center, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Swain</LastName><ForeName>Pamela M</ForeName><Initials>PM</Initials><AffiliationInfo><Affiliation>Metro International Biotech, Worcester, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lehman</LastName><ForeName>Phoebe</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Metro International Biotech, Worcester, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lavu</LastName><ForeName>Siva</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Metro International Biotech, Worcester, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Livingston</LastName><ForeName>David J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Metro International Biotech, Worcester, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bhasin</LastName><ForeName>Shalender</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Research Program in Men's Health: Aging and Metabolism, Boston Claude D. Pepper Older Americans Independence Center, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Metro International Biotech</Agency><Country /></Grant><Grant><GrantID>P30AG031679</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Aging Cell</MedlineTA><NlmUniqueID>101130839</NlmUniqueID><ISSNLinking>1474-9718</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">1‐methylnicotinamide</Keyword><Keyword MajorTopicYN="N">2PY</Keyword><Keyword MajorTopicYN="N">NAD+ augmentation in COVID‐19</Keyword><Keyword MajorTopicYN="N">NAD+ metabolites</Keyword><Keyword MajorTopicYN="N">NAD+ turnover</Keyword><Keyword MajorTopicYN="N">SARS‐CoV‐2 infection</Keyword><Keyword MajorTopicYN="N">nicotinamide</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>7</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>2</Day><Hour>7</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>2</Day><Hour>7</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>2</Day><Hour>0</Hour><Minute>43</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39354697</ArticleId><ArticleId IdType="doi">10.1111/acel.14326</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Al‐Shabany, A. J., Moody, A. J., Foey, A. D., &amp; Billington, R. A. (2016). Intracellular NAD+ levels are associated with LPS‐induced TNF‐alpha release in pro‐inflammatory macrophages. Bioscience Reports, 36, e00301.</Citation></Reference><Reference><Citation>Altay, O., Arif, M., Li, X., Yang, H., Aydin, M., Alkurt, G., Kim, W., Akyol, D., Zhang, C., Dinler‐Doganay, G., Turkez, H., Shoaie, S., Nielsen, J., Boren, J., Olmuscelik, O., Doganay, L., Uhlen, M., &amp; Mardinoglu, A. (2021). Combined metabolic activators accelerates recovery in mild‐to‐moderate COVID‐19. Advanced Science, 8, e2101222.</Citation></Reference><Reference><Citation>Bar, A., Olkowicz, M., Tyrankiewicz, U., Kus, E., Jasinski, K., Smolenski, R. T., Skorka, T., &amp; Chlopicki, S. (2017). Functional and biochemical endothelial profiling in vivo in a murine model of endothelial dysfunction; comparison of effects of 1‐Methylnicotinamide and angiotensin‐converting enzyme inhibitor. Frontiers in Pharmacology, 8, 183.</Citation></Reference><Reference><Citation>Bhasin, S., Seals, D., Migaud, M., Musi, N., &amp; Baur, J. A. (2023). Nicotinamide adenine dinucleotide in aging biology: Potential applications and many unknowns. Endocrine Reviews, 44, 1047–1073.</Citation></Reference><Reference><Citation>Bhatraju, P. K., Ghassemieh, B. J., Nichols, M., Kim, R., Jerome, K. R., Nalla, A. K., Greninger, A. L., Pipavath, S., Wurfel, M. M., Evans, L., Kritek, P. A., West, T. E., Luks, A., Gerbino, A., Dale, C. R., Goldman, J. D., O'Mahony, S., &amp; Mikacenic, C. (2020). Covid‐19 in critically ill patients in the Seattle region—case series. The New England Journal of Medicine, 382, 2012–2022.</Citation></Reference><Reference><Citation>Block, T., &amp; Kuo, J. (2022). Rationale for nicotinamide adenine dinucleotide (NAD+) metabolome disruption as a pathogenic mechanism of post‐acute COVID‐19 syndrome. Clinical Pathology, 15, 2632010X221106986.</Citation></Reference><Reference><Citation>Bolger, A. M., Lohse, M., &amp; Usadel, B. (2014). Trimmomatic: A flexible trimmer for Illumina sequence data. Bioinformatics, 30, 2114–2120.</Citation></Reference><Reference><Citation>Brady, P. N., Goel, A., &amp; Johnson, M. A. (2019). Poly(ADP‐ribose) polymerases in host‐pathogen interactions, inflammation, and immunity. Microbiology and Molecular Biology Reviews, 83, e00038‐18.</Citation></Reference><Reference><Citation>Breton, M., Costemale‐Lacoste, J.‐F., Li, Z., Lafuente‐Lafuente, C., Belmin, J., &amp; Mericskay, M. (2020). Blood NAD levels are reduced in very old patients hospitalized for heart failure. Experimental Gerontology, 139, 111051.</Citation></Reference><Reference><Citation>Camacho‐Pereira, J., Tarragó, M. G., Chini, C. C., Nin, V., Escande, C., Warner, G. M., Puranik, A. S., Schoon, R. A., Reid, J. M., Galina, A., &amp; Chini, E. N. (2016). CD38 dictates age‐related NAD decline and mitochondrial dysfunction through an SIRT3‐dependent mechanism. Cell Metabolism, 23, 1127–1139.</Citation></Reference><Reference><Citation>Campagna, R., Mateuszuk, Ł., Wojnar‐Lason, K., Kaczara, P., Tworzydło, A., Kij, A., Bujok, R., Mlynarski, J., Wang, Y., Sartini, D., Emanuelli, M., &amp; Chlopicki, S. (2021). Nicotinamide N‐methyltransferase in endothelium protects against oxidant stress‐induced endothelial injury. Biochimica et Biophysica Acta, Molecular Cell Research, 1868, 119082.</Citation></Reference><Reference><Citation>Chen, G., Wu, D., Guo, W., Cao, Y., Huang, D., Wang, H., Wang, T., Zhang, X., Chen, H., Yu, H., Zhang, X., Zhang, M., Wu, S., Song, J., Chen, T., Han, M., Li, S., Luo, X., Zhao, J., &amp; Ning, Q. (2020). Clinical and immunological features of severe and moderate coronavirus disease 2019. The Journal of Clinical Investigation, 130, 2620–2629.</Citation></Reference><Reference><Citation>Clement, J., Wong, M., Poljak, A., Sachdev, P., &amp; Braidy, N. (2019). The plasma NAD+ metabolome is dysregulated in “normal” aging. Rejuvenation Research, 22, 121–130.</Citation></Reference><Reference><Citation>Cummings, M. J., Baldwin, M. R., Abrams, D., Jacobson, S. D., Meyer, B. J., Balough, E. M., Aaron, J. G., Claassen, J., Rabbani, L. E., Hastie, J., Hochman, B. R., Salazar‐Schicchi, J., Yip, N. H., Brodie, D., &amp; O'Donnell, M. R. (2020). Epidemiology, clinical course, and outcomes of critically ill adults with COVID‐19 in New York City: A prospective cohort study. Lancet, 395, 1763–1770.</Citation></Reference><Reference><Citation>Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., &amp; Gingeras, T. R. (2013). STAR: Ultrafast universal RNA‐seq aligner. Bioinformatics, 29, 15–21.</Citation></Reference><Reference><Citation>Ferrell, M., Wang, Z., Anderson, J. T., Li, X. S., Witkowski, M., DiDonato, J. A., Hilser, J. R., Hartiala, J. A., Haghikia, A., Cajka, T., Fiehn, O., Sangwan, N., Demuth, I., König, M., Steinhagen‐Thiessen, E., Landmesser, U., Tang, W. H., Allayee, H., &amp; Hazen, S. L. (2024). A terminal metabolite of niacin promotes vascular inflammation and contributes to cardiovascular disease risk. Nature Medicine, 30, 1–11.</Citation></Reference><Reference><Citation>Garten, A., Schuster, S., Penke, M., Gorski, T., De Giorgis, T., &amp; Kiess, W. (2015). Physiological and pathophysiological roles of NAMPT and NAD metabolism. Nature Reviews Endocrinology, 11, 535–546.</Citation></Reference><Reference><Citation>Heer, C. D., Sanderson, D. J., Voth, L. S., Alhammad, Y. M. O., Schmidt, M. S., Trammell, S. A. J., Perlman, S., Cohen, M. S., Fehr, A. R., &amp; Brenner, C. (2020). Coronavirus infection and PARP expression dysregulate the NAD metabolome: An actionable component of innate immunity. The Journal of Biological Chemistry, 295, 17986–17996.</Citation></Reference><Reference><Citation>Hoffmann, M., Kleine‐Weber, H., Schroeder, S., Kruger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N. H., Nitsche, A., Muller, M. A., Drosten, C., &amp; Pohlmann, S. (2020). SARS‐CoV‐2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell, 181, 271–280.e8.</Citation></Reference><Reference><Citation>Hogan, K. A., Chini, C. C. S., &amp; Chini, E. N. (2019). The multi‐faceted Ecto‐enzyme CD38: Roles in immunomodulation, cancer, aging, and metabolic diseases. Frontiers in Immunology, 10, 1187.</Citation></Reference><Reference><Citation>Hong, G., Zheng, D., Zhang, L., Ni, R., Wang, G., Fan, G. C., Lu, Z., &amp; Peng, T. (2018). Administration of nicotinamide riboside prevents oxidative stress and organ injury in sepsis. Free Radical Biology &amp; Medicine, 123, 125–137.</Citation></Reference><Reference><Citation>Izadpanah, A., Mudd, J. C., Garcia, J. G., Srivastav, S., Abdel‐Mohsen, M., Palmer, C., Goldman, A. R., Kolls, J. K., Qin, X., &amp; Rappaport, J. (2023). SARS‐CoV‐2 infection dysregulates NAD metabolism. Frontiers in Immunology, 14, 1158455.</Citation></Reference><Reference><Citation>Komatsu, M., Kanda, T., Urai, H., Kurokochi, A., Kitahama, R., Shigaki, S., Ono, T., Yukioka, H., Hasegawa, K., Tokuyama, H., Kawabe, H., Wakino, S., &amp; Itoh, H. (2018). NNMT activation can contribute to the development of fatty liver disease by modulating the NAD (+) metabolism. Scientific Reports, 8, 8637.</Citation></Reference><Reference><Citation>Lenglet, A., Liabeuf, S., Bodeau, S., Louvet, L., Mary, A., Boullier, A., Lemaire‐Hurtel, A. S., Jonet, A., Sonnet, P., Kamel, S., &amp; Massy, Z. A. (2016). N‐methyl‐2‐pyridone‐5‐carboxamide (2PY)‐major metabolite of nicotinamide: An update on an old uremic toxin. Toxins, 8, 339.</Citation></Reference><Reference><Citation>Li, Y., Yang, X., He, Y., Wang, W., Zhang, J., Zhang, W., Jing, T., Wang, B., &amp; Lin, R. (2017). Negative regulation of NLRP3 inflammasome by SIRT1 in vascular endothelial cells. Immunobiology, 222, 552–561.</Citation></Reference><Reference><Citation>Liao, Y., Smyth, G. K., &amp; Shi, W. (2014). FeatureCounts: An efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics, 30, 923–930.</Citation></Reference><Reference><Citation>Liu, Q., Zhou, Y. H., &amp; Yang, Z. Q. (2016). The cytokine storm of severe influenza and development of immunomodulatory therapy. Cellular &amp; Molecular Immunology, 13, 3–10.</Citation></Reference><Reference><Citation>Love, M. I., Huber, W., &amp; Anders, S. (2014). Moderated estimation of fold change and dispersion for RNA‐seq data with DESeq2. Genome Biology, 15, 550.</Citation></Reference><Reference><Citation>Mason, R. J. (2020). Pathogenesis of COVID‐19 from a cell biology perspective. The European Respiratory Journal, 55, 2000607.</Citation></Reference><Reference><Citation>McReynolds, M. R., Chellappa, K., Chiles, E., Jankowski, C., Shen, Y., Chen, L., Descamps, H. C., Mukherjee, S., Bhat, Y. R., Lingala, S. R., Chu, Q., Botolin, P., Hayat, F., Doke, T., Susztak, K., Thaiss, C. A., Lu, W., Migaud, M. E., Su, X., … Baur, J. A. (2021). NAD(+) flux is maintained in aged mice despite lower tissue concentrations. Cell Systems, 12, 1160–1172.e1164.</Citation></Reference><Reference><Citation>Mehta, P., McAuley, D. F., Brown, M., Sanchez, E., Tattersall, R. S., Manson, J. J., &amp; HLH Across Speciality Collaboration, UK. (2020). COVID‐19: Consider cytokine storm syndromes and immunosuppression. Lancet, 395, 1033–1034.</Citation></Reference><Reference><Citation>Migaud, M., Gandotra, S., Chand, H. S., Gillespie, M. N., Thannickal, V. J., &amp; Langley, R. J. (2020). Metabolomics to predict antiviral drug efficacy in COVID‐19. American Journal of Respiratory Cell and Molecular Biology, 63, 396–398.</Citation></Reference><Reference><Citation>Nejabati, H. R., Mihanfar, A., Pezeshkian, M., Fattahi, A., Latifi, Z., Safaie, N., Valiloo, M., Jodati, A. R., &amp; Nouri, M. (2018). N1‐methylnicotinamide (MNAM) as a guardian of cardiovascular system. Journal of Cellular Physiology, 233, 6386–6394.</Citation></Reference><Reference><Citation>Novak, K. R. (2022). COVID‐19: Are we facing secondary pellagra which cannot simply Be cured by vitamin B3? International Journal of Molecular Sciences, 23, 4309.</Citation></Reference><Reference><Citation>Pedersen, S. F., &amp; Ho, Y. C. (2020). SARS‐CoV‐2: A storm is raging. The Journal of Clinical Investigation, 130, 2202–2205.</Citation></Reference><Reference><Citation>Pencina, K., Lavu, S., Dos Santos, M., Beleva, Y. M., Cheng, M., Livingston, D., &amp; Bhasin, S. (2022). MIB‐626, an Oral formulation of a microcrystalline unique polymorph of beta‐nicotinamide mononucleotide, increases circulating nicotinamide adenine dinucleotide and its metabolome in middle‐aged and older adults. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences, 78, 90–96.</Citation></Reference><Reference><Citation>Pencina, K. M., Valderrabano, R., Wipper, B., Orkaby, A. R., Reid, K. F., Storer, T. W., Lin, A. P., Merugumala, S., Wilson, L., Latham, N. K., Ghattas‐Puylara, C., Ozimek, N., Cheng, M., Bhargava, A., Memish‐Beleva, Y., Lawney, B., Lavu, S., Swain, P. M., Apte, R. S., … Bhasin, S. (2023). Nicotinamide adenine dinucleotide augmentation in overweight or obese middle‐aged and older adults: A physiologic study. The Journal of Clinical Endocrinology &amp; Metabolism, 108, 1968–1980.</Citation></Reference><Reference><Citation>Perla‐Kajan, J., &amp; Jakubowski, H. (2022). COVID‐19 and one‐carbon metabolism. International Journal of Molecular Sciences, 23, 4181.</Citation></Reference><Reference><Citation>Qin, C., Zhou, L., Hu, Z., Zhang, S., Yang, S., Tao, Y., Xie, C., Ma, K., Shang, K., Wang, W., &amp; Tian, D. S. (2020). Dysregulation of immune response in patients with coronavirus 2019 (COVID‐19) in Wuhan, China. Clinical Infectious Diseases, 71, 762–768.</Citation></Reference><Reference><Citation>Radenkovic, D., R., &amp; Verdin, E. (2020). Clinical evidence for targeting NAD therapeutically. Pharmaceuticals, 13, 247.</Citation></Reference><Reference><Citation>Raines, N. H., Cheung, M. D., Wilson, L. S., Edberg, J. C., Erdmann, N. B., Schmaier, A. A., Berryhill, T. F., Manickas‐Hill, Z., Li, J. Z., Yu, X. G., Agarwal, A., Barnes, S., &amp; Parikh, S. M. (2021). Nicotinamide adenine dinucleotide biosynthetic impairment and urinary metabolomic alterations observed in hospitalized adults with COVID‐19‐related acute kidney injury. Kidney International Reports, 6, 3002–3013.</Citation></Reference><Reference><Citation>Raines, N. H., Ganatra, S., Nissaisorakarn, P., Pandit, A., Morales, A., Asnani, A., Sadrolashrafi, M., Maheshwari, R., Patel, R., Bang, V., Shreyder, K., Brar, S., Singh, A., Dani, S. S., Knapp, S., Poyan Mehr, A., Brown, R. S., Zeidel, M. L., Bhargava, R., … Parikh, S. M. (2021). Niacinamide may Be associated with improved outcomes in COVID‐19‐related acute kidney injury: An observational study. Kidney360, 2, 33–41.</Citation></Reference><Reference><Citation>Ramos, I., &amp; Fernandez‐Sesma, A. (2015). Modulating the innate immune response to influenza a virus: Potential therapeutic use of anti‐inflammatory drugs. Frontiers in Immunology, 6, 361.</Citation></Reference><Reference><Citation>Rutkowski, B., Slominska, E., Szolkiewicz, M., Smolenski, R. T., Striley, C., Rutkowski, P., &amp; Swierczynski, J. (2003). N‐methyl‐2‐pyridone‐5‐carboxamide: A novel uremic toxin? Kidney International, 63, S19–S21.</Citation></Reference><Reference><Citation>Sahoo, B. R., Crook, A. A., Pattnaik, A., Torres‐Gerena, A. D., Khalimonchuk, O., Powers, R., Franco, R., &amp; Pattnaik, A. K. (2023). Redox regulation and metabolic dependency of zika virus replication: Inhibition by Nrf2‐antioxidant response and NAD (H) antimetabolites. Journal of Virology, 97, e0136322.</Citation></Reference><Reference><Citation>Sims, C. A., Guan, Y., Mukherjee, S., Singh, K., Botolin, P., Davila, A., Jr., &amp; Baur, J. A. (2018). Nicotinamide mononucleotide preserves mitochondrial function and increases survival in hemorrhagic shock. JCI Insight, 3, e120182.</Citation></Reference><Reference><Citation>Slominska, E. M., Kowalik, K., Smolenski, R. T., Szolkiewicz, M., Rutkowski, P., Rutkowski, B., &amp; Swierczynski, J. (2006). Accumulation of poly (ADP‐ribose) polymerase inhibitors in children with chronic renal failure. Pediatric Nephrology, 21, 800–806.</Citation></Reference><Reference><Citation>Slominska, E. M., Rutkowski, P., Smolenski, R. T., Szutowicz, A., Rutkowski, B., &amp; Swierczynski, J. (2004). The age‐related increase in N‐methyl‐2‐pyridone‐5‐carboxamide (NAD catabolite) in human plasma. Molecular and Cellular Biochemistry, 267, 25–30.</Citation></Reference><Reference><Citation>Takahashi, R., Kanda, T., Komatsu, M., Itoh, T., Minakuchi, H., Urai, H., Kuroita, T., Shigaki, S., Tsukamoto, T., Higuchi, N., Ikeda, M., Yamanaka, R., Yoshimura, N., Ono, T., Yukioka, H., Hasegawa, K., Tokuyama, H., Wakino, S., &amp; Itoh, H. (2022). The significance of NAD + metabolites and nicotinamide N‐methyltransferase in chronic kidney disease. Scientific Reports, 12, 6398.</Citation></Reference><Reference><Citation>Wu, Z., &amp; McGoogan, J. M. (2020). Characteristics of and important lessons from the coronavirus disease 2019 (COVID‐19) outbreak in China: Summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA, 323, 1239–1242.</Citation></Reference><Reference><Citation>Xiao, N., Nie, M., Pang, H., Wang, B., Hu, J., Meng, X., Li, K., Ran, X., Long, Q., Deng, H., Chen, N., Li, S., Tang, N., Huang, A., &amp; Hu, Z. (2021). Integrated cytokine and metabolite analysis reveals immunometabolic reprogramming in COVID‐19 patients with therapeutic implications. Nature Communications, 12, 1618.</Citation></Reference><Reference><Citation>Zeidler, J. D., Kashyap, S., Hogan, K. A., &amp; Chini, E. N. (2022). Implications of the NADase CD38 in COVID pathophysiology. Physiological Reviews, 102, 339–341.</Citation></Reference><Reference><Citation>Zheng, M., Schultz, M. B., &amp; Sinclair, D. A. (2022). NAD(+) in COVID‐19 and viral infections. Trends in Immunology, 43, 283–295.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>